US medical center, Mayo Clinic, has signed a pre-clinical research agreement with MagForce.

Under the agreement, Mayo Clinic will begin a research program to investigate the preclinical efficacy of the MagForce’s NanoTherm therapy in treating pancreatic and liver cancer.

Mayo Clinic will provide funds for the study, while the project will be directed by Dev Mukhopadhyay, professor of Biochemistry/Molecular Biology.

MagForce R&D medical affairs vice president Hoda Tawfik said due to the poor overall survival rates and the severe side effects of chemotherapeutics, the current standard of care for pancreatic cancer is an enormous challenge in oncology.

"In a pilot study MagForce could show the feasibility of the use of its NanoTherm therapy in pancreatic cancer patients with first hints of activity," Tawfik added.

"A positive outcome of this new project would be the first important milestone to set up a clinical development program in gastrointestinal cancer in cooperation with medical key opinion leaders throughout the United States."

The company said it will use the results of preclinical proof-of-concept to file NanoTherm therapy’s premarket application to the US Food and Drug Administration.